June 2008
Worldwide Biotech;Jun2008, Vol. 20 Issue 6, p1
Trade Publication
This arricle announces the initiation of Phase I clinical development of ESBATech AG's lead product development candidate, ESBA105, in ophthalmology. The study is designed to evaluate the safety, tolerability and pharmacokinetic profile of ESBA105, when delivered topically via eye drops in healthy volunteers. It is being conducted as a single and repeated dose escalation study in Switzerland.


Related Articles

  • Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. Rordorf, Christiane M.; Choi, Les; Marshall, Paul; Mangold, James B. // Clinical Pharmacokinetics;2005, Vol. 44 Issue 12, p1247 

    Lumiracoxib (Prexige®) is a selective cyclo-oxygenase (COX)-2 inhibitor developed for the treatment of osteoarthritis, rheumatoid arthritis and acute pain. Lumiracoxib possesses a carboxylic acid group that makes it weakly acidic (acid dissociation constant [pKa] 4.7), distinguishing it from...

  • Merck Serono's Phase III Parkinson's trial meets endpoint.  // PharmaWatch: CNS;Mar2009, Vol. 8 Issue 3, p7 

    The article reports on the outcome of the Merck Serono's first Phase III Parkinson's trial of safinamide. It states that increasing the daily "ON" time in mid-to late stage Parkinson's disease patients with motor fluctuations by 1.3 hours, patients experience the best level of motor functioning....

  • First-in-man study of heparin antagonist PMX-6005.  // Cardiovascular Devices & Drugs;Apr2009, Vol. 15 Issue 4, p18 

    The article reports on the completion of the first-in-man clinical study conducted by PolyMedix on its heparin antagonist drug PMX-60056. The author claimed that the study was able to meet the Phase I goals of defining both a limiting single dose for ten-minute infusions and the plasma...

  • Index to Abstract Authors.  // Clinical Pharmacology & Therapeutics;Mar2014 Supplement, Vol. 95, pS104 

    An author index on the subject of clinical pharmacology and therapeutics is presented.

  • Keyword Index.  // Clinical Pharmacology & Therapeutics;Mar2014 Supplement, Vol. 95, pS111 

    A keyword index on the subject of clinical pharmacology and therapeutics is presented.

  • Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes? Ensom, H.; Davis, G.A.; Cropp, C.D.; Ensom, R.J.; Ensom, M H // Clinical Pharmacokinetics;1998, Vol. 34 Issue 4, p265 

    Clinical pharmacokinetics emerged as a clinical discipline in the late 1960s and early 1970s. Clinical pharmacokinetic monitoring (CPM) helped many pharmacists to enter the clinical arena, but the focus was more on the pharmacists and tools. With the widespread acceptance of pharmaceutical care...

  • Clinical Pharmacokinetics of Nucleoside Analogues. Johnson, Stephen A. // Clinical Pharmacokinetics;2000, Vol. 39 Issue 1, p5 

    This review establishes the pharmacokinetic characteristics of the major nucleoside analogues with cytotoxic activity. Cytarabine, pentostatin, fludarabine, cladribine and gemcitabine are all prodrugs whose plasma pharmacokinetics do not fully reflect their therapeutic activity; after cellular...

  • Clinical pharmacokinetics of ropinirole. Kaye, C.M.; Nicholls, B. // Clinical Pharmacokinetics;2000, Vol. 39 Issue 4, p243 

    Ropinirole is a selective non-ergoline dopamine D2 receptor agonist indicated for use in treating Parkinson's disease. When taken as oral tablets, ropinirole is rapidly and almost completely absorbed, and it is extensively distributed from the vascular compartment. The bioavailability is...

  • Clinical Pharmacokinetics of Pravastatin. Hatanaka, Tomomi // Clinical Pharmacokinetics;2000, Vol. 39 Issue 6, p397 

    Pravastatin, one of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) widely used in the management of hypercholesterolaemia, has unique pharmacokinetic characteristics among the members of this class. Many in vivo and in vitro human and animal studies suggest...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics